| Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy E Ravussin, SR Smith, JA Mitchell, R Shringarpure, K Shan, H Maier, ... Obesity 17 (9), 1736-1743, 2009 | 338 | 2009 |
| Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies WJ Sandborn, S Vermeire, L Peyrin-Biroulet, MC Dubinsky, J Panes, ... The Lancet 401 (10383), 1159-1171, 2023 | 79 | 2023 |
| Concurrent improvement in both binge eating and depressive symptoms with naltrexone/bupropion therapy in overweight or obese subjects with major depressive disorder in an open … AI Guerdjikova, B Walsh, K Shan, AE Halseth, E Dunayevich, SL McElroy Advances in Therapy 34, 2307-2315, 2017 | 52 | 2017 |
| Combining regression quantile estimators K Shan, Y Yang Statistica Sinica, 1171-1191, 2009 | 37 | 2009 |
| Method‐of‐use study of naltrexone sustained release (SR)/bupropion SR on body weight in individuals with obesity A Halseth, K Shan, B Walsh, K Gilder, K Fujioka Obesity 25 (2), 338-345, 2017 | 36 | 2017 |
| Increased variability and abnormalities in pancreatic enzyme concentrations in otherwise asymptomatic subjects with type 2 diabetes J Malloy, K Gurney, K Shan, P Yan, S Chen Diabetes, metabolic syndrome and obesity: targets and therapy, 419-424, 2012 | 30 | 2012 |
| Pramlintide improved measures of glycemic control and body weight in patients with type I diabetes mellitus undergoing continuous subcutaneous insulin infusion therapy K Herrmann, JP Frias, SV Edelman, K Lutz, K Shan, S Chen, D Maggs, ... Postgraduate medicine 125 (3), 136-144, 2013 | 25 | 2013 |
| Quality of life, binge eating and sexual function in participants treated for obesity with sustained release naltrexone/bupropion A Halseth, K Shan, K Gilder, M Malone, L Acevedo, K Fujioka Obesity Science & Practice 4 (2), 141-152, 2018 | 20 | 2018 |
| Etrasimod 2 mg once daily as treatment for moderately to severely active ulcerative colitis: results from the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials WJ Sandborn, S Vermeire, L Peyrin-Biroulet, MC Dubinsky, J Panes, ... Gastroenterology 162, 1395, 2022 | 11 | 2022 |
| Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity 2009; 17: 1736-1743 E Ravussin, SR Smith, JA Mitchell, R Shringarpure, K Shan, H Maier Přejít k původnímu zdroji... Přejít na PubMed, 2009 | 8 | 2009 |
| Effects of pramlintide in patients with type 2 diabetes mellitus: an analysis using daily insulin dose tertiles K Herrmann, K Shan, SC Brunell, S Chen Endocrine practice 20 (10), 1070-1075, 2014 | 7 | 2014 |
| P490 Etrasimod for the treatment of ulcerative colitis: up to 2.5 years of pooled safety data from global clinical trials S Vermeire, L Peyrin-Biroulet, J Panés, M Regueiro, PG Kotze, ... Journal of Crohn's and Colitis 17 (Supplement_1), i619-i620, 2023 | 6 | 2023 |
| P207 Effects of fluconazole, gemfibrozil, and rifampin on the pharmacokinetics, safety, and tolerability of etrasimod C Lee, C Taylor, Y Tang, L Villa-Caballero, K Shan, A Randle, JS Grundy Gut 71 (Suppl 1), A142-A142, 2022 | 4 | 2022 |
| A Phase 1 Study Evaluating the Bioequivalence of the Proposed Commercial and Clinical Formulations of Etrasimod 2mg, and the Effect of Food on the Pharmacokinetics of the … C Lee, A Ramaiya, Y Tang, A Sapone, K Shan, A Randle, J Grundy JOURNAL OF CROHNS & COLITIS 16, I029-I029, 2022 | 3 | 2022 |
| Clinical remission demonstrated with oral ozanimod in the overall population and across multiple subgroups of patients with moderately to severely active ulcerative colitis in … BG Feagan, WJ Sandborn, G D'Haens, S Hanauer, DC Wolf, S Vermeire, ... Journal Of Crohns & Colitis 13, S464-S464, 2019 | 3 | 2019 |
| Metabolic effects of metreleptin treatment in familial partial lipodystrophy (FPL) EA Oral, A Neidert, B Hakim, S Miller, K Shan, B Irani, K Lutz, J Chan Endocrine Reviews Conference: 94th Annual Meeting and Expo of the Endocrine …, 2012 | 2 | 2012 |
| 948 ETRASIMOD FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 2.5 YEARS OF POOLED SAFETY DATA FROM GLOBAL CLINICAL TRIALS S Vermeire, L Peyrin-Biroulet, J Panés, MD Regueiro, PG Kotze, ... Gastroenterology 164 (6), S-207, 2023 | 1 | 2023 |
| Effect on body weight of naltrexone/bupropion in overweight and obese participants with type 2 diabetes and cardiovascular risk factors in a large, randomized, double-blind study SR Smith, JB Buse, K Gilder, K Shan, A Halseth Diabetes 66, A556-A556, 2017 | 1 | 2017 |
| Effect of Naltrexone/Bupropion on Cardiovascular Events in Overweight and Obese Participants with Type 2 Diabetes and Cardiovascular Risk Factors in a Large, Randomized, Double … JB Buse, SR Smith, K Gilder, K Shan, A Halseth Diabetes 66, A557-A557, 2017 | 1 | 2017 |
| Improvement in patient-assessed quality of life, eating behavior, and sexual function after 26 weeks of naltrexone/bupropion compared with usual care K Fujioka, B Walsh, AE Halseth, K Shan, TA Wadden Diabetes 64, A308-A308, 2015 | 1 | 2015 |
